COPENHAGEN (Reuters) -Novo Nordisk’s head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.
Head of Novo’s rare disease unit, Ludovic Helfgott, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, Novo Nordisk said in a statement.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
Comments